home / stock / ebs / ebs news


EBS News and Press, Emergent Biosolutions Inc. From 07/30/21

Stock Information

Company Name: Emergent Biosolutions Inc.
Stock Symbol: EBS
Market: NYSE
Website: emergentbiosolutions.com

Menu

EBS EBS Quote EBS Short EBS News EBS Articles EBS Message Board
Get EBS Alerts

News, Short Squeeze, Breakout and More Instantly...

EBS - Emergent cites inquiries from U.S. authorities regarding its COVID-19 vaccine manufacturing

In a regulatory filing yesterday, Emergent BioSolutions (EBS +2.4%) said it had received inquiries and subpoenas from a range of U.S. authorities regarding its ability to conduct COVID-19 vaccine manufacturing. The company’s production plant in Baltimore was subject to an FDA insp...

EBS - Emergent BioSolutions Inc. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Emergent BioSolutions Inc. 2021 Q2 - Results - Earnings Call Presentation

EBS - Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript

Image source: The Motley Fool. Emergent BioSolutions inc (NYSE: EBS) Q2 2021 Earnings Call Jul 29, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions inc (EBS) Q2 2021 Earnings Call Transcript

EBS - Emergent Biosolutions' (EBS) CEO Bob Kramer on Q2 2021 Results - Earnings Call Transcript

Emergent Biosolutions, Inc. (EBS) Q2 2021 Earnings Conference Call July 29, 2021 5:00 PM ET Company Participants Bob Burrows – Investor Relations Bob Kramer – President and Chief Executive Officer Rich Lindahl – Chief Financial Officer Conference Call Participants Brandon...

EBS - Emergent Biosolutions EPS misses by $1.23, misses on revenue

Emergent Biosolutions (NYSE:EBS): Q2 Non-GAAP EPS of $0.33 misses by $1.23; GAAP EPS of $0.09 misses by $1.24. Revenue of $397.5M (+0.7% Y/Y) misses by $3.67M. Reaffirmed 2021 Outlook: Total revenues $1,700 - $1,900M; NARCAN® Nasal Spray $305 - $325M; Anthrax vaccines $280...

EBS - Emergent BioSolutions Reports Financial Results For Second Quarter 2021

Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. “Our second quarter performance demonstr...

EBS - Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid...

EBS - Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes accidental. Professional football player Darren Waller and lifestyle influencer Dani ...

EBS - IDNA And Healthcare Dashboard For July

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July

EBS - Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the ...

Previous 10 Next 10